A randomized, double-blind multicenter study to assess the safety and efficacy of a six month oral treatment with the chymase inhibitor BAY 1142524 at a dose of 25 mg BID in comparison to placebo on top of standard of care in patients with reduced left-ventricular ejection fraction (LVEF ≤ 45%) after acute myocardial infarction (CHIARA MIA 2).

Trial Profile

A randomized, double-blind multicenter study to assess the safety and efficacy of a six month oral treatment with the chymase inhibitor BAY 1142524 at a dose of 25 mg BID in comparison to placebo on top of standard of care in patients with reduced left-ventricular ejection fraction (LVEF ≤ 45%) after acute myocardial infarction (CHIARA MIA 2).

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs BAY 1142524 (Primary)
  • Indications Left ventricular dysfunction
  • Focus Therapeutic Use
  • Acronyms CHIARA MIA 2
  • Sponsors Bayer
  • Most Recent Events

    • 07 Feb 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Aug 2018.
    • 11 Jan 2017 Status changed from not yet recruiting to recruiting.
    • 13 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top